Holen Sie sich die Stockscreener-App
0.2854
1.11%
-0.0032
Handel nachbörslich:
.27
-0.0154
-5.40%
Schlusskurs vom Vortag:
$0.2886
Offen:
$0.29
24-Stunden-Volumen:
197.40K
Relative Volume:
0.50
Marktkapitalisierung:
$20.40M
Einnahmen:
$391.70K
Nettoeinkommen (Verlust:
$-52.34M
KGV:
-0.3805
EPS:
-0.75
Netto-Cashflow:
$-45.92M
1W Leistung:
-0.56%
1M Leistung:
-32.86%
6M Leistung:
-76.02%
1J Leistung:
-91.16%
1-Tages-Spanne:
$0.265
$0.2912
1-Wochen-Bereich:
$0.2615
$0.3029
52-Wochen-Spanne:
$0.2425
$3.45
Ovid Therapeutics Inc Stock (OVID) Company Profile
Firmenname
Ovid Therapeutics Inc
Sektor
Branche
Telefon
212-776-4381
Adresse
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Vergleichen Sie OVID mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
0.2854 | 20.40M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-05 | Eingeleitet | Wedbush | Outperform |
| 2023-12-21 | Eingeleitet | BTIG Research | Buy |
| 2023-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2021-04-20 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-04-20 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Ovid Therapeutics Inc Aktie (OVID) Neueste Nachrichten
Ovid Therapeutics to Present at the 12th International Epilepsy Colloquium | Libero Quotidiano.it - Libero Quotidiano
Dravet Syndrome Treatment Market Future Business - openPR.com
Ovid Therapeutics stock hits 52-week low at $0.27 By Investing.com - Investing.com South Africa
Ovid Therapeutics stock hits 52-week low at $0.27 - Investing.com
Ovid Therapeutics Advances Pipeline Amid Financial Progress - TipRanks
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Key Brain Medicine Updates: Ovid Therapeutics Takes Center Stage at Major Healthcare Conference - Stock Titan
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $3.03 Consensus Target Price from Brokerages - Defense World
Ovid Therapeutics stock hits 52-week low at $0.35 amid downturn By Investing.com - Investing.com South Africa
Ovid Therapeutics stock hits 52-week low at $0.35 amid downturn - Investing.com Canada
HC Wainwright Lifts Earnings Estimates for Ovid Therapeutics - Defense World
FY2026 Earnings Forecast for OVID Issued By HC Wainwright - Defense World
Ovid Therapeutics (NASDAQ:OVID) Price Target Lowered to $4.00 at BTIG Research - Defense World
Ovid Therapeutics stock target cut to $2 at H.C. Wainwright By Investing.com - Investing.com Australia
Ovid Therapeutics stock target cut to $2 at H.C. Wainwright - Investing.com
BTIG cuts Ovid Therapeutics stock price target to $4 By Investing.com - Investing.com South Africa
BTIG cuts Ovid Therapeutics stock price target to $4 - Investing.com
Ovid Therapeutics stock hits 52-week low at $0.42 amid market challenges - Investing.com
Ovid Therapeutics stock hits 52-week low at $0.42 amid market challenges By Investing.com - Investing.com South Africa
West syndrome Pipeline 2025: Mechanism of Action, Route - openPR
Q1 EPS Forecast for Ovid Therapeutics Raised by Analyst - Defense World
What is Wedbush’s Estimate for OVID FY2029 Earnings? - Defense World
William Blair Forecasts Lower Earnings for Ovid Therapeutics - Defense World
What is William Blair’s Estimate for OVID Q1 Earnings? - Defense World
Wedbush Adjusts Price Target on Ovid Therapeutics to $3 From $4, Keeps Outperform Rating - MarketScreener
Ovid Therapeutics earnings beat by $0.04, revenue fell short of estimates - Investing.com Canada
Ovid Therapeutics’ Cybersecurity Challenges: Navigating IT Risks and Third-Party Dependencies - TipRanks
Ovid Therapeutics stock plunges to 52-week low of $0.46 - Investing.com India
Ovid Therapeutics stock plunges to 52-week low of $0.46 By Investing.com - Investing.com South Africa
Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Ovid Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Ovid Therapeutics Secures 2-Year Cash Runway as 3 Novel Drug Programs Progress - StockTitan
We're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate - Yahoo Finance
Ovid Therapeutics (OVID) Expected to Announce Earnings on Friday - Defense World
Trump's FDA chief pick Makary to face overhauling agency, keeping Kennedy happy -March 06, 2025 at 06:00 am EST - Marketscreener.com
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.03 Consensus Target Price from Brokerages - Defense World
Ovid Therapeutics appoints new board member and updates compensation policy - Investing.com India
Ovid Therapeutics appoints new board member and updates compensation policy By Investing.com - Investing.com South Africa
Ovid Therapeutics Expands Board with New Appointment - TipRanks
Ovid Therapeutics Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Ovid Therapeutics Appoints Dr. Stelios Papadopoulos To Board - citybiz
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors - GlobeNewswire
Finanzdaten der Ovid Therapeutics Inc-Aktie (OVID)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):